SCHEMBL6974476

SCHEMBL6974476

CN1CC2C[CH]CC2C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20799597 0.81 HRH3 (0.31)
SCHEMBL24866097 0.81 HRH3 (0.31)
SCHEMBL2271063 0.75 CHRNA7 (0.33)
SCHEMBL23267575 0.75 CHRNA7 (0.33)
SCHEMBL13849461 0.75 CHRNA7 (0.33)
SCHEMBL16538590 0.71 ALDH1A1 (0.40)
SCHEMBL1005825 0.71 HSD11B1 (0.31)
SCHEMBL16882865 0.69
SCHEMBL23265467 0.69
SCHEMBL21850190 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102727498-A Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha EXELIXIS INC LAMB PETER MATTHEWS DAVID 2012-10-17 CN claimed
CN-101959516-A Combination therapy comprising quinoxaline PI3K alpha inhibitors for the treatment of cancer EXELIXIS INC 2011-01-26 CN claimed
CN-101715345-A Methods of treatment using pyridopyrimidinone PI3K alpha inhibitors EXELIXIS INC 2010-05-26 CN claimed
US-20030176445-A1 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists PFIZER INC. 2003-09-18 US claimed
EP-1106615-B1 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists PFIZER (US) 2003-03-05 EP claimed
US-20020042421-A1 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists OKUMURA YOSHIYUKI (JP) 2002-04-11 US claimed
EP-1106615-A1 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists PFIZER INC. (US) 2001-06-13 EP claimed
US-10507209-B2 Quinazoline derivatives substituted by aniline, preparation method and use thereof XUANZHU PHARMA CO, LTD. (CN) 2019-12-17 US disclosed
US-9956222-B2 Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof Xuanzhu Pharma Co., Ltd. (CN) 2018-05-01 US disclosed
EP-2738156-B1 9-AMINOMETHYL SUBSTITUTED TETRACYCLINE COMPOUNDS KBP BIOSCIENCES USA INC (US) 2018-01-03 EP disclosed
US-20170333433-A1 QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF XUANZHU PHARMA CO, LTD. (CN) 2017-11-23 US disclosed
US-20170304305-A1 QUINAZOLINE DERIVATIVES SUBSTITUTED BY ANILINE, PREPARATION METHOD AND USE THEREOF XUANZHU PHARMA CO LTD (CN) 2017-10-26 US disclosed
US-9730934-B2 Quinazoline derivatives substituted by aniline, preparation method and use thereof Xuanzhu Pharma Co., Ltd. (CN) 2017-08-15 US disclosed
CN-102727498-A Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha EXELIXIS INC LAMB PETER MATTHEWS DAVID 2012-10-17 CN disclosed
CN-101959516-A Combination therapy comprising quinoxaline PI3K alpha inhibitors for the treatment of cancer EXELIXIS INC 2011-01-26 CN disclosed
CN-101715345-A Methods of treatment using pyridopyrimidinone PI3K alpha inhibitors EXELIXIS INC 2010-05-26 CN disclosed
US-20030176445-A1 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists PFIZER INC. 2003-09-18 US disclosed
EP-1106615-B1 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists PFIZER (US) 2003-03-05 EP disclosed
US-20020042421-A1 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists OKUMURA YOSHIYUKI (JP) 2002-04-11 US disclosed
EP-1106615-A1 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists PFIZER INC. (US) 2001-06-13 EP disclosed